…value Celldex on the assumption of $400 million in sales of CDX-110 in 2020, discounted back at a 30% rate.
However, this DCF analysis is based on a 100% probability of technical success for the CDX-110 program. It’s somewhat odd, IMO, that the author of such an article does not try to quantify this metric.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”